Acadia announces Phase 2 results for remlifanserin in Alzheimer’s disease psychosis
ACAD•Acadia said remlifanserin narrowly missed the Phase 2 study’s primary endpoint (p=0.0603) but met a key secondary endpoint (p=0.0077). The company said it will continue enrolling two Phase 3 studies and amend the program.
1. Phase 2 findings
Acadia Pharmaceuticals announced topline results from its Phase 2 RADIANT study of remlifanserin for Alzheimer’s disease psychosis. The drug showed a favorable safety profile, with adverse-event rates similar to placebo.
2. Endpoints and next steps
The study narrowly missed its primary SAPS H+D endpoint (p=0.0603) and showed nominal significance on the key secondary CGI-S-ADP endpoint (p=0.0077). Acadia said the dataset suggested no negative impact on motor symptoms or cognition, with no deaths in the remlifanserin treatment arms. The company will continue enrolling two ongoing Phase 3 studies and implement amendments to the program.
